Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Subject must be 18-55 years of age~Subject is able to provide written, personally signed and dated informed consent.~Subject is willing and able to comply with all of the testing and requirements defined in the protocol~Subject, who is a female, must not be pregnant.~Subject must have a satisfactory medical assessment with no clinically significant or relevant abnormalities.~Subject has a primary diagnosis of ADHD.~Subject has an adult ADHD-RS with prompts total score ≥28 at the baseline visit.~Subject must have a minimum level of intellectual functioning, as determined by the investigator.~Subject is able to swallow a capsule.~Subject is currently not on ADHD therapy or is not completely satisfied with any aspect of their current ADHD therapy.~Exclusion Criteria:~Subject has a current, comorbid psychiatric diagnosis with significant symptoms.~Subject is considered a suicide risk in the opinion of the investigator~Subject has a body mass index (BMI) of \<18.5 kg/m2 at the screening visit.~Subject has a BMI ≥40 kg/m2 at the screening visit.~Subject has a concurrent chronic or acute illness, disability, or other condition.~Subject has a history of seizure, a chronic or current tic disorder, or a current diagnosis of Tourette's disorder.~Subject has a history of moderate to severe hypertension.~Subject has a known history of symptomatic cardiovascular disease~Subject has a known family history of sudden cardiac death or ventricular arrhythmia.~Subject has any clinically significant ECG or clinically significant laboratory abnormality at the screening visit.~Subject has current abnormal thyroid function~Subject has a documented allergy, hypersensitivity, or intolerance to amphetamine or to any excipients in the investigational product.~Subject has failed to respond, to an adequate course(s) of amphetamine therapy.~Subject has a history of suspected substance abuse or dependence disorder.~Subject has a positive urine drug result at the screening visit (with the exception of subject's current stimulant therapy, if any) or Subject has taken another investigational product or has taken part in a clinical study within 30 days prior to the screening visit.~Subject has previously completed, has discontinued, or was withdrawn from this study.~Subject is taking any medication that is excluded or has not been appropriately washed out according to the protocol requirements.~Subject is required to take or anticipates the need to take medications that have CNS effects or affect performance.~Subject is female and is pregnant or lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- SHP465 12.5 mg (Type: EXPERIMENTAL): Subjects will receive SHP465 12.5 mg
- SHP465 37.5 mg (Type: EXPERIMENTAL): Subjects will receive SHP465 titrated up to 37.5 mg
- Placebo (Type: PLACEBO_COMPARATOR): Subjects will receive matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).